Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTO-100 in Major Depressive Disorder
NCT05419869Phase 2Completed
- Sponsor
- Alto Neuroscience
- Start
- Jun 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of amdiglurax in major depressive disorder (MDD), sponsored by Alto Neuroscience. Started Jun 2022; status: completed.
02
Drugs
amdiglurax
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05419869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05419869.